AstraZeneca

AstraZeneca's Tagrisso shows potential as a new standard of care in 1st-line EGFR-mutated lung cancer at ESMO 2017 Congress

9 September 2017 00:22

Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent benefit across all subgroups, including patients with and without brain metastases
Unprecedented median progression-free survival (PFS) of 18.9 months compared with 10.2 months for the current standard of care
Clinically-meaningful preliminary overall survival benefit
A

AstraZeneca presents superior progression-free survival for Imfinzi in the PACIFIC trial of patients with locally-advanced unresectable lung cancer

9 September 2017 00:22

Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine to show superior PFS in this setting
Data presented at the ESMO 2017 Congress follows FDA’s recent Breakthrough Therapy Designation for Imfinzi in locally advanced, unresectable lung cancer
The PACIFIC trial continues to evaluate the other primary endpoint, overall s

Förpackning märkt SelokenZOC 100 mg kan innehålla fel burk

7 September 2017 16:52

Vi vill uppmärksamma patienter som hämtat ut en förpackning med SelokenZOC 100 mg i burk med 100 tabletter, efter april i år, att kontrollera att den burk som ligger i förpackningen verkligen är märkt SelokenZOC 100 mg. Aktuellt varunummer är Vnr 543587, batchnummer VBBN.

Celgene and AstraZeneca provide update on the FUSION clinical trial programme

7 September 2017 14:02

AstraZeneca and MedImmune, its global biologics research and development arm, have been informed by partner Celgene that the US Food and Drug Administration (FDA) has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION programme.

Duaklir significantly improves lung function in COPD patients

7 September 2017 08:09

Phase III AMPLIFY trial demonstrateda statistically significant improvement in lung function in patients with COPD Study achieved the primary endpoints to support a New Drug Application (NDA) submission

Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma

6 September 2017 23:05

AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma

AstraZeneca to present data on next generation of biologics at European Respiratory Society International Congress 2017

4 September 2017 08:03

AstraZeneca and its global biologics research and development arm, MedImmune, will present new data on its respiratory portfolio and pipeline at the European Respiratory Society (ERS) International Congress, 9-13 September 2017 in Milan, Italy. The breadth and depth of science are reflected in the 48 accepted abstracts.....

AstraZeneca highlights latest advances in lung cancer at the ESMO 2017 Congress

31 Augusti 2017 08:11

More than 40 presentations, including data from two pivotal trials selected as late-breaking abstracts for oral presentation in the ESMO Presidential Symposia Phase III PACIFIC data reinforce potential of Imfinzi following US FDA breakthrough therapy designation in locally-advanced (Stage III) unresectable NSCLC

AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson’s disease

29 Augusti 2017 08:33

AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).
Alpha-synuclein (α-synuclein) is an aggregation-prone protein that contributes to the development of PD. This protein is the major const

Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer

28 Augusti 2017 08:03

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Faslodex (fulvestrant) 500mg as monotherapy for expanded use in women with hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, who have gone through menopause and have not received previous endocrine therapy.

Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack

24 Augusti 2017 08:03

AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment with Brilinta (ticagrelor) 60mg twice daily, versus placebo, in patients taking low-dose aspirin but still at high risk of an atherothrombotic event, a major cause of acute coronary syndrome and CV death.

Lynparza receives additional and broad approval in the US for ovarian cancer

17 Augusti 2017 21:27

AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the U.S. and Canada) today announced that the US Food and Drug Administration (FDA) has granted approval for the PARP inhibitor, Lynparza (olaparib).

Nordiska registerdata visar att SGLT-2-hämmare, jämfört med andra glukossänkande läkemedel, förknippas med en minskad risk för prematur hjärt-kärlsjukdom och död

16 Augusti 2017 09:00

Resultat publicerade i The Lancet Diabetes & Endocrinology från observationsstudien CVD-REAL Nordic, baserad på svenska registerdata, indikerar att behandling av typ 2-diabetes med SGLT-2-hämmare i klinisk praxis är associerad med minskad risk för kardiovaskulära insjuknanden, särskilt med dödlig utgång, jämfört med andra glukossänkande läkemedel, även hos patienter utan känd hjärt-kärlsjukdom.

US FDA accepts regulatory submission for acalabrutinib and grants priority review

2 Augusti 2017 08:04

AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for the New Drug Application (NDA) for acalabrutinib, a highly-selective, potent, Bruton tyrosine kinase (BTK) inhibitor.

Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma

1 Augusti 2017 08:07

AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib .

Imfinzi granted breakthrough therapy designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer

31 Juli 2017 08:04

Fourth Breakthrough Therapy Designation for an AstraZeneca New Oncology medicine in three years.

Tagrisso significantly improves progression-free survival in the phase III FLAURA trial for lung cancer

27 Juli 2017 09:19

AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with Tagrisso (osimertinib) compared to current 1st-line standard-of-care treatment......

AstraZeneca reports initial results from the ongoing MYSTIC trial in stage IV lung cancer

27 Juli 2017 09:13

AstraZeneca and MedImmune today announced progression-free survival (PFS) results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab versus platinum-based standard-of-care (SoC) chemotherapy in previously-untreated patients with metastatic (Stage IV) 1st-line non-small cell lung cancer

AstraZeneca and Merck establish strategic oncology collaboration

27 Juli 2017 09:09

AstraZeneca and Merck & Co., Inc., today announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment.

AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2017

27 Juli 2017 09:06

Pascal Soriot, koncernchef, kommenterar resultatet:
”Vårt resultat för första halvåret var i linje med förväntningarna eftersom vi påverkades av effekterna av patentutgången för Crestor och Seroquel XR i USA. Vi fortsatte att leverera nyskapande forskning inom alla våra forskningsområden, i synnerhet inom onkologi. Imfinzi lanserades mot cancer i urinblåsan, samtidigt som vi publicerade banbryt

Ämnen: Industri, tillverkning